Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita

Journal of Investigative Dermatology

Volumn 135, Issue 3, 2015, Pages 916-919

  Iwata, Hiroaki ^a   Pipi, Elena ^a   Möckel, Nicole ^a   Sondermann, Peter ^b   Vorobyev, Artem ^a   Van Beek, Nina ^a   Zillikens, Detlef ^a   Ludwig, Ralf J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b SuppreMol GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DERMATOLOGICAL AGENT; DOUBLE STRANDED DNA ANTIBODY; FC RECEPTOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT ANTIGEN; RECOMBINANT SOLUBLE CD32 ANTIGEN; UNCLASSIFIED DRUG; ANTIGEN ANTIBODY COMPLEX; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN PRESENTATION; BODY SURFACE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; EFFECTOR CELL; EPIDERMOLYSIS BULLOSA ACQUISITA; EXPERIMENTAL SKIN DISEASE; IMMUNOFLUORESCENCE; IMMUNOPHARMACOLOGY; IN VITRO STUDY; LETTER; LEUKOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; ANIMAL; DISEASE MODEL; HUMAN; METABOLISM; TREATMENT OUTCOME;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; MICE; REACTIVE OXYGEN SPECIES; RECEPTORS, IGG; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84922621645     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.451     Document Type: Article

References (15)

1. Collin M, Ehlers M (2013) The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies. Exp Dermatol 22:511-4
2. Engineer L, Ahmed AR (2001) Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 44:818-28
3. Getahun A, Dahlstrom J, Wernersson S et al. (2004) IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc gamma receptors. J Immunol 172:5269-76
4. Gupta R, Woodley DT, Chen M (2012) Epidermolysis bullosa acquisita. Clin Dermatol 30:60-9
5. Ierino FL, Powell MS, McKenzie IF et al. (1993) Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction. J Exp Med 178: 1617-28
6. Iwata H, Bieber K, Tiburzy B et al. (2013) B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita. J Immunol 191:2978-88
7. Kasperkiewicz M, Nimmerjahn F, Wende S et al. (2012) Genetic identification and functional validation of FcgRIV as key molecule in autoantibody-induced tissue injury. J Pathol 228:8-19
8. Kleinau S, Martinsson P, Heyman B (2000) Induction and suppression of collageninduced arthritis is dependent on distinct fcgamma receptors. J Exp Med 191: 1611-6
9. Ludwig RJ, Kalies K, Kohl J et al. (2013) Emerging treatments for pemphigoid diseases. Trends Mol Med 19:501-12
10. Magnusson SE, Andrén M, Nilsson KE et al. (2008) Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb. Clin Immunol 127:225-33
11. McKenzie SE, Taylor SM, Malladi P et al. (1999) The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 162:4311-8
12. Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet 381:320-32
13. Varin N, Sautès C, Galinha A et al. (1989) Recombinant soluble receptors for the Fc gamma portion inhibit antibody production in vitro. Eur J Immunol 19:2263-8
14. Werwitzke S, Trick D, Sondermann P et al. (2008) Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32) Ann Rheum Dis 67: 154-61
15. Woodley DT, Burgeson RE, Lunstrum G et al. (1988) Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest 81: 683-7